Shots:
- The US FDA received BLA, plus a request for a priority review of apitegromab to improve motor function in pts with SMA who are on SMN-targeted therapy. The EMA’s MAA to be filed in Q1’25
- The BLA was supported by the P-III (SAPPHIRE) & P-II (TOPAZ) trial, where SAPPHIRE met its 1EP of 1.8-point improvement in HFMSE compared to PBO in 52wks. (topline data shared in 2024), with additional findings to be presented at the MDA Clinical & Scientific Conference 2025
- Additionally, apitegromab will be evaluated in the P-II (OPAL) trial for pts (<2yrs.) who are on approved SMN therapy (nusinersen, risdiplam, or onasemnogene abeparvovec), with the study to begin in mid-2025
Ref: Scholar Rock | Image: Scholar Rock
Related News:- Amgen Receives EC’s Approval for Blincyto to Treat Philadelphia Chromosome-Negative CD19-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
